Search

Adolescents and young adults (AYA)

Spotlight on AYAAdolescents and young adults (AYA) with hematologic diseases are a unique group with special characteristics and needs. In recent years, the challenges related to the management of AYA (particularly in relation to cancer) have increasingly been recognized.

HARMONY: Innovative Medicines Initiative approves € 40 million project for better care of patients with hematologic malignancies

Feb 01 2017

HARMONY will capture, integrate, analyze and harmonize anonymous patient data from high-quality multidisciplinary sources to unlock valuable knowledge on multiple myeloma (MM), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkins lymphoma (NHL), myelodysplastic syndromes (MDS)…

IVDR

As of May 26, 2022, the new EU In Vitro Diagnostic medical devices Regulation (IVDR) comes into effect.

FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement

Dec 13 2023

We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).